Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer
1 other identifier
observational
300
1 country
1
Brief Summary
To evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 7, 2024
CompletedStudy Start
First participant enrolled
December 9, 2024
CompletedFirst Posted
Study publicly available on registry
December 13, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
February 14, 2025
February 1, 2025
4.1 years
December 7, 2024
February 13, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
rate of disease progression
cervical lymph node metastases and persistent tumors confirmed by pathology, Distant metastasis detected by CT, positron emission tomography, or bone scan if there were suspicious symptoms.
through study completion, an average of 6 months
Secondary Outcomes (5)
rate of complications
1 week
rate of volume reduction
through study completion, an average of 6 months
rate of tumor disappearance
through study completion, an average of 6 months
Tg level
through study completion, an average of 6 months
rate of delayed surgery
through study completion, an average of 1 year
Study Arms (1)
ultrasound-guided thermal ablation
ultrasound-guided thermal ablation
Interventions
microwave ablation, radiofrequency ablation, laser ablation
Eligibility Criteria
patients with recurrent thyroid cancer
You may qualify if:
- patient received thyroidectomy for thyroid cancer
- recurrent lesions were pathologically proven to be malignant by core-needle biopsy or fine needle aspiration
- no evidence of distant metastases.
- follow-up period ≥12 months
You may not qualify if:
- coagulation disorder, serious heart, respiratory, liver, or renal failure
- dysfunction of the vocal cord on the opposite side
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yukun Luo
Chinese PLA General Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
December 7, 2024
First Posted
December 13, 2024
Study Start
December 9, 2024
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2030
Last Updated
February 14, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share